Common use of Monitoring & Reporting requirements Clause in Contracts

Monitoring & Reporting requirements. 10.1 Regular informal contact with Prostate Cancer UK to discuss the progress of the Project is welcomed and encouraged. 10.2 An interim progress report must be submitted to Prostate Cancer UK within 30 days of the first anniversary of the Start Date and within 30 days of each subsequent anniversary. A detailed final report must be submitted within three months of the end of the Grant Period. Reports must be approved by the Principal Investigator in such formats and containing such information as is reasonably requested by Prostate Cancer UK, including effective lay summaries. Such reports shall state any divergence from the original timetable and budget for the Project and must highlight any potential for commercial exploitation of the results of the research funded by the Grant. 10.3 The Principal Investigator is required to submit accurate information on an annual basis on the outputs from the Project in a format as specified by Prostate Cancer UK. This reporting must continue beyond the Grant Period for a length of time as agreed by Prostate Cancer UK and the Principal Investigator upon completion of the Grant, up to a maximum of 10 years. Failure to comply with this clause 10.3 may result in the Research Institution and Principal Investigator being barred from receiving any further grants from Prostate Cancer UK. Payment of the final invoice will not be contingent upon any supplementary reporting requested after the submission of the final report (to be submitted within three months of the end of the Grant Period as stipulated in clause 10.2). 10.4 Continuation of funding is dependent on adequate progress of the Project, as described in Schedule One and in the Grant Application, and as judged by Prostate Cancer UK under the advice of the Research Advisory Committee. Adequate progress shall include, but is not limited to; achieving stipulated milestones, keeping to the stipulated schedule, remaining within budget and addressing the key aims and hypotheses. If at any stage Prostate Cancer UK consider the progress of the Project to be unsatisfactory, or if the work undertaken is not in accordance with that set out in Schedule One and the Grant Application, then this would constitute a material breach, enabling Prostate Cancer UK to terminate the Agreement. 10.5 Late or overdue reports as set out in 10.2 and 10.3 will result in Prostate Cancer UK withholding payment of any outstanding and/or future claims until such report is received and accepted as satisfactory by Prostate Cancer UK. 10.6 Failure by the Research Institution to submit any report and/or information set out in clauses 10.2 and

Monitoring & Reporting requirements. 10.1 Regular informal contact with Prostate Cancer UK to discuss the progress of the Project is welcomed and encouraged. 10.2 An interim progress report must be submitted to Prostate Cancer UK within 30 days of the first anniversary of the Start Date and within 30 days of each subsequent anniversary. A detailed final report must be submitted within three months of the end of the Grant Period. Reports must be approved by the Principal Investigator in such formats and containing such information as is reasonably requested by Prostate Cancer UK, including effective lay summaries. Such reports shall state any divergence from the original timetable and budget for the Project and must highlight any potential for commercial exploitation of the results of the research funded by the Grant. 10.3 The Research Institution must ensure that the Principal Investigator is required to submit submits accurate information on an annual basis on the progress and outputs from the Project during the Grant Period, in a format as specified by Prostate Cancer UK. This reporting must continue beyond the Grant Period for a length of time and at a frequency as agreed by Prostate Cancer UK and the Principal Investigator upon completion of the Grant, up to a maximum of 10 years. The minimum expectation is for a report to be submitted at one, two, five and ten years after the end of the Grant Period. Failure to comply with this clause 10.3 may result in the Research Institution and Principal Investigator being barred from receiving any further grants from Prostate Cancer UK. Payment of the final invoice will not be contingent upon any supplementary reporting requested after the submission of the final report (to be submitted within three months of the end of the Grant Period as stipulated in clause 10.2). 10.4 Continuation of funding is dependent on adequate progress of the Project, as described in Schedule One and in the Grant Application, and as judged by Prostate Cancer UK under the advice of the Research Advisory Committee. Adequate progress shall include, but is not limited to; achieving stipulated milestones, keeping to the stipulated schedule, remaining within budget and addressing the key aims and hypotheses. If at any stage Prostate Cancer UK consider the progress of the Project to be unsatisfactory, or if the work undertaken is not in accordance with that set out in Schedule One and the Grant Application, then this would constitute a material breach, enabling Prostate Cancer UK to terminate the Agreement. 10.5 Late or overdue reports as set out in 10.2 and 10.3 will result in Prostate Cancer UK withholding payment of any outstanding and/or future claims until such report is received and accepted as satisfactory by Prostate Cancer UK. 10.6 Failure by the Research Institution to submit any report and/or information set out in clauses 10.2 and